Shuttle Pharmaceuticals (NASDAQ:SHPH) Releases Quarterly Earnings Results

Shuttle Pharmaceuticals (NASDAQ:SHPH) announced its quarterly earnings results on Friday. The company reported ($0.43) EPS for the quarter, FiscalAI reports.

Shuttle Pharmaceuticals Stock Performance

SHPH stock opened at $0.67 on Friday. Shuttle Pharmaceuticals has a 1 year low of $0.50 and a 1 year high of $6.19. The stock’s 50 day moving average price is $0.85 and its 200 day moving average price is $1.47. The firm has a market cap of $3.72 million, a P/E ratio of -0.06 and a beta of 0.38.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at approximately $26,000. Boothbay Fund Management LLC purchased a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at approximately $37,000. Ikarian Capital LLC purchased a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at approximately $124,000. Finally, Connective Capital Management LLC purchased a new position in Shuttle Pharmaceuticals in the 3rd quarter valued at about $357,000. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, May 4th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .